Newly Discovered Cannabinoid Combinations that Treat Non-Hodgkin Lymphoma

6개월 전

Non-Hodgkin lymphoma cells have higher expression of CB1 and CB2 cannabinoid receptors in the mRNA of the cell compared to regular cells, ready to be stimulated by cannabinoids to self-destruct. A recent study shows that certain cannabinoid combinations effectively treat My-La and HuT-78 cell lines of lymphoma, resulting in up to 50% 86% cell death respectively.

My-La.jpg
My-La cell line viability against various cannabinoid compounds

S4: a compound consisting of CBD (98.3%), THC (0.3%), cannabigerol (CBG 0.2%), a-bisabolol (0.9%) and cannabidivarin (CBDV 0.09%).

S5: a compound consisting of CBG (58.8%) and CBD (38.2%), THC (0.7%) and cannabichromene (CBC 0.4%).

DOXO: doxorubicin aka Adriamycin ® or Rubex®

HuT-78.jpg
HuT-78 cell line viability against various cannabinoid compounds

The following cannabinoid compounds were found to have anti-lymphoma properties at varying concentrations:

  • CBD+CBG
  • CBD+CBG+CBC
  • CBD+CBG+THC
  • CBD+CBG+THC+CBC

Pure CBD in some concentrations causes My-La cell proliferation rather than apoptosis (death); however, when added to other cannabinoids, like CBG, THC, or CBC, it has anti-cancer properties.

Source:


Mazuz, M., Tiroler, A., Moyal, L., Hodak, E., Nadarajan, S., Vinayaka, A. C., Gorovitz-Haris, B., Lubin, I., Drori, A., Drori, G., Cauwenberghe, O. V., Faigenboim, A., Namdar, D., Amitay-Laish, I., & Koltai, H. (2020). Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo. Oncotarget, Vol. 11(issue 13), Pp. 1141–1156.

Authors get paid when people like you upvote their post.
If you enjoyed what you read here, create your account today and start earning FREE STEEM!
STEEMKR.COM IS SPONSORED BY
ADVERTISEMENT
Sort Order:  trending

This post has been rewarded by the Steem Community Curation Project. #communitycuration06
RESPECT
#SteemOn